Peijia Medical Limited (HKG:9996)
6.95
+0.12 (1.76%)
Jan 21, 2026, 3:12 PM HKT
Peijia Medical Revenue
Peijia Medical had revenue of 353.38M CNY in the half year ending June 30, 2025, with 57.15% growth. This brings the company's revenue in the last twelve months to 667.66M, up 29.03% year-over-year. In the year 2024, Peijia Medical had annual revenue of 615.48M with 39.53% growth.
Revenue (ttm)
667.66M CNY
Revenue Growth
+29.03%
P/S Ratio
6.25
Revenue / Employee
637.69K CNY
Employees
1,047
Market Cap
4.57B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 615.48M | 174.36M | 39.53% |
| Dec 31, 2023 | 441.13M | 190.29M | 75.86% |
| Dec 31, 2022 | 250.83M | 114.30M | 83.71% |
| Dec 31, 2021 | 136.53M | 97.88M | 253.21% |
| Dec 31, 2020 | 38.66M | 19.96M | 106.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |